Odanacatib

Odanacatib Uses, Dosage, Side Effects, Food Interaction and all others data.

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.

Increases bone mineral density and reduces risk of fractures in osteoporosis .

Odanacatib
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Odanacatib
Generic	Odanacatib
Odanacatib Other Names	Odanacatib
Type
Formula	C₂₅H₂₇F₄N₃O₃S
Weight	Average: 525.56 Monoisotopic: 525.170925567
Protein binding	97.5% bound to plasma proteins .
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in osteoporosis .

How Odanacatib works

Odanacatib inhibits cathepsin K, likely by binding to its active site . Cathepsin K is a cysteine protease enzyme which is secreted by osteoclasts . Cathepsin K is responsible for the breakdown of collagen in the bone matrix as part of bone resorption. The inhibition of this enzyme results in decreased bone resorption without affecting bone deposition resulting in increased bone mineral density. This increased bone mineral density strengthens the bone which leads to fewer fractures in osteoporosis.

Toxicity

Odanacatib was found to increase the risk of stroke . No further toxicological studies have been performed.

Volume of Distribution

100L

Elimination Route

Tmax of 2-6h . The absolute bioavailabilities observed with 30mg and 50 mg doses are 70% and 30% respectively. When taken with high fat meals the 50mg dose's bioavailability increases to 49% and tmax increases to 10.5h .